Mingyu Liang, MB, PhD
Professor and Kohler Co. Chair in Physiology; Director, Center of Systems Molecular Medicine; Vice-Chair for Interdisciplinary and Translational Research
Postdoctoral Fellow, Nephrology, Mayo Clinic and Foundation, 2000
Postdoctoral Fellow, Physiology, Medical College of Wisconsin, 2002
MB - Medicine, Shanghai Medical University, 1994
Honors and Awards
2017: Distinguished Lectureship in Physiological Genomics Research, American Physiological Society
2015-2020: Center Director, American Heart Association Strategically Focused Hypertension Research Center (including basic, clinical and population research)
2012: Henry Pickering Bowditch Award, American Physiological Society
2009: Outstanding Teacher of the Year, MCW Graduate School
1994: Outstanding Graduate, Shanghai Municipality
Associate Editor: Physiol Genomics (2007-2015); Compr Physiol (2017-present)
Editorial board: J Am Soc Nephrol; Hypertension
Genetics and Genomics | Molecular and Cellular Physiology | Renal Physiology
I am a molecular systems medicine researcher. The current work in my laboratory focuses on three areas: (epi)genomics and precision medicine, regulatory RNA, and cellular metabolism, as they relate to hypertension and cardiovascular and kidney diseases. We have a translational, multidisciplinary, and programmatic research platform in our laboratory where we integrate human research with research in animals, human induced pluripotent stem cells (iPSC), and other model systems using approaches of physiology, genetics, biochemistry, molecular biology, genome editing, and big data analysis.
For a complete list of our laboratory’s publications since 2002, search PubMed for “Mingyu Liang”.
Research Area 1: (Epi)genomics and precision medicine
We develop innovative approaches to precision medicine for common cardiovascular and renal diseases with a particular focus on the incorporation of tissue functional genomic analysis. We study molecular regulatory networks, including genomic and epigenomic mechanisms, underlying physiology and disease.
1. Williams AM, Jensen DM, Pan X, Liu P, Liu J, Huls S, Regner KR, Iczkowski KA, Wang F, Li J, Gallan AJ, Wang T, Baker MA, Liu Y, Lalehzari N, Liang M. Histologically resolved small RNA maps in primary focal segmental glomerulosclerosis indicate progressive changes within glomerular and tubulointerstitial regions. Kidney Int. 2022. Online ahead of print.
2. Mishra MK, Liang EY, Geurts AM, Auer PWL, Liu P, Rao S, Greene AS, Liang M, Liu Y. Comparative and Functional Genomic Resource for Mechanistic Studies of Human Blood Pressure-Associated Single Nucleotide Polymorphisms. Hypertension 2020; 75: 859-868.
3. Baker MA, Davis SJ, Liu P, Pan X, Williams AM, Iczkowski KA, Gallagher ST, Bishop K, Regner KR, Liu Y, Liang M. Tissue-Specific MicroRNA Expression Patterns in Four Types of Kidney Disease. J Am Soc Nephrol. 2017; 28: 2985-2992.
4. Kotchen TA, Cowley AW Jr, Liang M. Ushering hypertension into the new era of precision medicine. JAMA 2016; 315: 343-4.
Research Area 2: Regulatory RNA
The general significance of microRNAs in the regulation of gene expression, cellular function, and disease development is widely recognized. However, the specific role of many microRNAs, and other regulatory RNA such as long non-coding RNA, in physiological and disease processes remain unknown. Our laboratory investigates the role of regulatory RNA in hypertension and cardiovascular and renal injury in humans and model systems.
1. Cheng Y, Wang D, Wang F, Liu J, Huang B, Baker MA, Yin J, Wu R, Liu X, Regner KR, Usa K, Liu Y, Zhang C, Dong L, Geurts AM, Wang N, Miller SS, He Y, Liang M. Endogenous miR-204 protects the kidney against chronic injury in hypertension and diabetes. J Am Soc Nephrol. 2020; 31: 1539-1554.
2. Widlansky ME, Jensen DM, Wang J, Liu Y, Geurts AM, Kriegel AJ, Liu P, Ying R, Zhang G, Casati M, Chu C, Malik M, Branum A, Tanner MJ, Tyagi S, Usa K, Liang M. miR-29 contributes to normal endothelial function and can restore it in cardiometabolic disorders. EMBO Mol Med 2018; e8046.
3. Mladinov D, Liu Y, Mattson DL, Liang M. MicroRNAs contribute to the maintenance of cell-type-specific physiological characteristics: miR-192 targets Na+/K+-ATPase β1. Nucleic Acids Res. 2013; 41: 1273-83.
4. Xu X, Kriegel AJ, Liu Y, Usa K, Mladinov D, Liu H, Fang Y, Ding X, Liang M. Delayed ischemic preconditioning contributes to renal protection by upregulation of miR-21. Kidney Int. 2012; 82: 1167-75.
5. Liu Y, Taylor NE, Lu L, Usa K, Cowley AW Jr, Ferreri NR, Yeo NC, and Liang M. Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension 2010; 55: 974-82.
6. Tian Z, Greene AS, Pietrusz JL, Matus IR, and Liang M. microRNA-target pairs in rat kidneys identified through microRNA microarray, proteomic, and bioinformatic analysis. Genome Res 2008; 18: 404-411.
Research Area 3: Cellular metabolism
Our laboratory routinely combines exploratory approaches and hypothesis-driven approaches to discover novel disease mechanisms in humans and animal models. Recent discoveries that we are exploring in depth include novel roles of abnormalities in cellular metabolism in the development of hypertension and tissue injury.
1. Tian Z, Liang M. Renal Metabolism and Hypertension. Nat Commun. 2021; 12: 963.
2. Cheng Y, Song H, Pan X, Xue H, Wan Y, Wang T, Tian Z, Hou E, Lanza IR, Liu P, Liu Y, Laud PW, Usa K, He Y, Liang M. Urinary Metabolites Associated with Blood Pressure on a Low- or High-Sodium Diet. Theranostics 2018; 8: 1468-1480.
3. Hou E, Sun N, Zhang F, Zhao C, Usa K, Liang M, Tian Z. Malate and Aspartate Increase L-arginine and Nitric Oxide and Attenuate Hypertension. Cell Rep. 2017; 19: 1631-1639.
4. Tian Z, Liu Y, Usa K, Mladinov D, Fang Y, Ding X, Greene AS, Cowley AW Jr, Liang M. Novel Role of Fumarate Metabolism in Dahl Salt-Sensitive Hypertension. Hypertension 2009; 54: 255-60.
Please contact Dr. Liang if you are interested in a post-doctoral fellow or pre-doctoral student position in his laboratory.
Toward Precision Medicine: Circadian Rhythm of Blood Pressure and Chronotherapy for Hypertension - 2021 NHLBI Workshop Report.
(Gumz ML, Shimbo D, Abdalla M, Balijepalli RC, Benedict C, Chen Y, Earnest DJ, Gamble KL, Garrison SR, Gong MC, Hogenesch JB, Hong Y, Ivy JR, Joe B, Laposky AD, Liang M, MacLaughlin EJ, Martino TA, Pollock DM, Redline S, Rogers A, Dan Rudic R, Schernhammer ES, Stergiou GS, St-Onge MP, Wang X, Wright J, Oh YS.) Hypertension. 2023 Mar;80(3):503-522 PMID: 36448463 PMCID: PMC9931676 12/01/2022
Metabolic responses of normal rat kidneys to a high salt intake.
(Shimada S, Hoffmann BR, Yang C, Kurth T, Greene AS, Liang M, Dash RK, Cowley AW.) bioRxiv. 2023 Jan 31 PMID: 36711564 PMCID: PMC9882299 01/31/2023
Broad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications.
(Jensen DM, Han P, Mangala LS, Lopez-Berestein G, Sood AK, Liu J, Kriegel AJ, Usa K, Widlansky ME, Liang M.) Mol Ther. 2022 Nov 02;30(11):3462-3476 PMID: 35965413 PMCID: PMC9637778 SCOPUS ID: 2-s2.0-85136662053 08/16/2022
Histologically resolved small RNA maps in primary focal segmental glomerulosclerosis indicate progressive changes within glomerular and tubulointerstitial regions.
(Williams AM, Jensen DM, Pan X, Liu P, Liu J, Huls S, Regner KR, Iczkowski KA, Wang F, Li J, Gallan AJ, Wang T, Baker MA, Liu Y, Lalehzari N, Liang M.) Kidney Int. 2022 Apr;101(4):766-778 PMID: 35114200 PMCID: PMC8940673 SCOPUS ID: 2-s2.0-85125312317 02/04/2022
Unique Associations of DNA Methylation Regions With 24-Hour Blood Pressure Phenotypes in Black Participants.
(Roberts ML, Kotchen TA, Pan X, Li Y, Yang C, Liu P, Wang T, Laud PW, Chelius TH, Munyura Y, Mattson DL, Liu Y, Cowley AW Jr, Kidambi S, Liang M.) Hypertension. 2022 Apr;79(4):761-772 PMID: 34994206 PMCID: PMC8917053 SCOPUS ID: 2-s2.0-85126152389 01/08/2022
Substrate-dependent differential regulation of mitochondrial bioenergetics in the heart and kidney cortex and outer medulla.
(Tomar N, Zhang X, Kandel SM, Sadri S, Yang C, Liang M, Audi SH, Cowley AW Jr, Dash RK.) Biochim Biophys Acta Bioenerg. 2022 Feb 01;1863(2):148518 PMID: 34864090 PMCID: PMC8957717 SCOPUS ID: 2-s2.0-85120828118 12/06/2021
Advancing Physiology with Expanded Multi-Omics.
(Liang M, Cowley AW Jr, Greene AS, Geurts AM, Liu P, Liu Y, Rao S.) Function (Oxf). 2022;3(4):zqac031 PMID: 35801086 PMCID: PMC9247404 07/09/2022
Theodore Allen Kotchen, MD: June 27, 1938-July 6, 2021.
(Cowley AW Jr, Kidambi S, Liang M, Grim C, Hamet P.) Hypertension. 2021 Dec;78(6):1674-1676 PMID: 34719936 SCOPUS ID: 2-s2.0-85121955751 11/02/2021
miR-204: Molecular Regulation and Role in Cardiovascular and Renal Diseases.
(Liu J, Liu Y, Wang F, Liang M.) Hypertension. 2021 Aug;78(2):270-281 PMID: 34176282 PMCID: PMC8283800 SCOPUS ID: 2-s2.0-85109560313 06/29/2021
Dietary Sodium Restriction Results in Tissue-Specific Changes in DNA Methylation in Humans.
(Kidambi S, Pan X, Yang C, Liu P, Roberts ML, Li Y, Wang T, Laud PW, Liu Y, Rubens M, Thomas R, Widlansky ME, Beyer AM, Liu Y, Cowley AW Jr, Kotchen TA, Munyura Y, Moosreiner A, Mattson DL, Liang M.) Hypertension. 2021 Aug;78(2):434-446 PMID: 34120454 PMCID: PMC9299531 SCOPUS ID: 2-s2.0-85109563974 06/15/2021
Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention.
(Perry TR, Roberts ML, Sunkara B, Maddula R, McLeish T, Gomez J, Lucas J, Rayan D, Patel S, Liang M, Bosnjak ZJ, Brown SA.) Curr Oncol Rep. 2021 May 03;23(7):77 PMID: 33937943 PMCID: PMC8088904 SCOPUS ID: 2-s2.0-85105159465 05/04/2021
Global identification and characterization of tRNA-derived RNA fragment landscapes across human cancers.
(Sun X, Yang J, Yu M, Yao D, Zhou L, Li X, Qiu Q, Lin W, Lu B, Chen E, Wang P, Chen W, Tao S, Xu H, Williams A, Liu Y, Pan X, Cowley AW Jr, Lu W, Liang M, Liu P, Lu Y.) NAR Cancer. 2020 Dec;2(4):zcaa031 PMID: 34316691 PMCID: PMC8210304 07/29/2021